Cayman Gefitinib

Gefitinib is an EGFR inhibitor (IC₅₀s = 0.023-0.079 µM).¹ It inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC₅₀s = 0.2-0.4 µM).² Gefitinib (0.1 to 1 µM) induces apoptosis and inhibits EGFR autophosphorylation in the same cells. In vivo, gefitinib (1.25, 2.5, and 5 mg/kg) reduces tumor volume and increases survival in a GEO mouse xenograft model. Formulations containing gefitinib have been used in the treatment of non-small cell lung cancer (NSCLC).

WARNING This product is not for human or veterinary use.